Candida Liquid
NDC Package 81825-0004-1
Package Information
Candida (baptisia tinctoria, echinacea purp, glycyrrhiza glabra, astragalus, candida alb, borax, calc carb, kreosotum, lycopodium, nux vom, phosphoricum ac, pulsatilla, sepia, thuja occ, nat phos, nitricum ac) liquids is uSES: Temporarily relieves symptoms associated with vaginal yeast.**. This formulation utilizes a liquid delivery system. Marketed by Zorex International, this product is identified by NDC 81825-0004.
Identification & Billing
Clinical Specifications
- ASTRAGALUS NUTTALLII LEAF 6 [hp_X]/mL
- BAPTISIA TINCTORIA WHOLE 4 [hp_X]/mL
- CANDIDA ALBICANS 200 [hp_C]/mL
- ECHINACEA PURPUREA WHOLE 4 [hp_X]/mL
- GLYCYRRHIZA GLABRA 4 [hp_X]/mL
- LYCOPODIUM CLAVATUM SPORE 30 [hp_C]/mL
- NITRIC ACID 30 [hp_C]/mL
- OYSTER SHELL CALCIUM CARBONATE, CRUDE 30 [hp_C]/mL
- PHOSPHORIC ACID 30 [hp_C]/mL
- PULSATILLA VULGARIS WHOLE 30 [hp_C]/mL
- SEPIA OFFICINALIS JUICE 30 [hp_C]/mL
- SODIUM BORATE 30 [hp_C]/mL
- SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE 30 [hp_C]/mL
- STRYCHNOS NUX-VOMICA SEED 30 [hp_C]/mL
- THUJA OCCIDENTALIS LEAFY TWIG 30 [hp_C]/mL
- WOOD CREOSOTE 30 [hp_C]/mL
- Allergens - [CS]
- Allergens - [CS]
- Cell-mediated Immunity - [PE] (Physiologic Effect)
- Dietary Proteins - [CS]
- Fungal Proteins - [CS]
- Increased Histamine Release - [PE] (Physiologic Effect)
- Increased IgG Production - [PE] (Physiologic Effect)
- Non-Standardized Food Allergenic Extract - [EPC] (Established Pharmacologic Class)
- Non-Standardized Fungal Allergenic Extract - [EPC] (Established Pharmacologic Class)
- Non-Standardized Plant Allergenic Extract - [EPC] (Established Pharmacologic Class)
- Plant Proteins - [CS]
- Seed Storage Proteins - [CS]
Regulatory & Marketing
Hierarchy Structure
- 81825 - Zorex International
- 81825-0004 - Candida
- 81825-0004-1 - 30 mL in 1 BOTTLE, DROPPER
- 81825-0004 - Candida
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 81825-0004-1 identifies a specific commercial package of 30 ml in 1 bottle, dropper of Candida, a human over the counter drug labeled by Zorex International. This liquid is formulated for oral use and contains astragalus nuttallii leaf; baptisia tinctoria whole; candida albicans; echinacea purpurea whole; glycyrrhiza glabra; lycopodium clavatum spore; nitric acid; oyster shell calcium carbonate, crude; phosphoric acid; pulsatilla vulgaris whole; sepia officinalis juice; sodium borate; sodium phosphate, dibasic, heptahydrate; strychnos nux-vomica seed; thuja occidentalis leafy twig; wood creosote as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Zorex International on December 22, 2021. The current certification is valid through December 31, 2026.
How is this Zorex International product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 81825000401. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.